Biomedical research: Increasing value, reducing waste
e-publications@bond (Bond University)Published 1 January 2014
Macleod, Malcolm, Michie, Susan, Roberts, Ian, Dirnagl, Ulrich, Chalmers, Iain, Ioannidis, John
Citations797
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
Global biomedical and public health research involves billions of dollars and millions of people. Although this vast enterprise has led to substantial health improvements, many more gains are possible if the waste and inefficiency in the ways that biomedical research is chosen, designed, done, analysed, regulated, managed, disseminated, and reported can be addressed.
Keywords
MedicineEconomics, Econometrics and FinanceHealth Professions
Implementation ScienceThe behaviour change wheel: A new method for characterising and designing behaviour change interventions
13,641 Citations2011Susan Michie, Maartje M. van Stralen +1 more
Interventions and policies to change behaviour can be usefully characterised by means of a BCW comprising: a 'behaviour system' at the hub, encircled by intervention functions and then by policy categories, and a new framework aimed at overcoming their limitations is developed.
Journal of the Royal Society of MedicineThe answer is 17 years, what is the question: understanding time lags in translational research
3,385 Citations2011Zoë Slote Morris, Steven Wooding +1 more
The study concludes that understanding lags first requires agreeing models, definitions and measures, which can be applied in practice, and a second task would be to develop a process by which to gather these data.
The LancetAvoidable waste in the production and reporting of research evidence
2,254 Citations2009Iain Chalmers, Paul Glasziou
The LancetIncreasing value and reducing waste in research design, conduct, and analysis
1,592 Citations2014John P. A. Ioannidis, Sander Greenland +6 more
Potential solutions for problems related to the research workforce are proposed, including improvements in protocols and documentation, consideration of evidence from studies in progress, standardisation of research efforts, optimisation and training of an experienced and non-conflicted scientific workforce, and reconsideration of scientific reward systems.
The LancetHow to increase value and reduce waste when research priorities are set
1,434 Citations2014Iain Chalmers, Michael B. Bracken +7 more
This report discusses how avoidable waste can be considered when research priorities are set and recommends ways to improve the yield from basic research, and the transparency of processes by which funders prioritise important uncertainties should be increased.
The LancetReducing waste from incomplete or unusable reports of biomedical research
1,359 Citations2014Paul Glasziou, Douglas G. Altman +7 more
The high amount of waste at all stages in medical research warrants future investment in the monitoring of and research into reporting of research, and active implementation of the findings to ensure that research reports better address the needs of the range of research users.
The LancetIncreasing value and reducing waste: addressing inaccessible research
907 Citations2014An‐Wen Chan, Fujian Song +7 more
Three main actions are warranted: academic institutions and funders should reward investigators who fully disseminate their research protocols, reports, and participant-level datasets, and standards for the content of protocols and full study reports should be rigorously developed and adopted for all types of health research.
Clinical ChemistryThe Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum
575 Citations2009N. Leigh Anderson
An analysis of all US Food and Drug Administration approvals for protein-based assays through 2008 reveals 109 unique protein targets in plasma or serum, as well as 62 additional tests for peptides, protein posttranslational modifications, protein complexes, autoantibodies against endogenous proteins, and blood cell proteins.
The LancetIncreasing value and reducing waste in biomedical research regulation and management
562 Citations2014Rustam Al‐Shahi Salman, Elaine Beller +7 more
Researchers and research managers should increase the efficiency of recruitment, retention, data monitoring, and data sharing in research through use of research designs known to reduce inefficiency, and further research should be done to learn how efficiency can be increased.
The LancetMapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?
468 Citations2013John‐Arne Røttingen, Sadie Regmi +8 more
It is confirmed that substantial gaps in the global landscape of health R&D remain, especially for and in low-income and middle-income countries, and too few investments are targeted towards the health needs of these countries.
JAMAFunding of US Biomedical Research, 2003-2008
335 Citations2010E. Ray Dorsey
After a decade of doubling, the rate of increase in biomedical research funding slowed from 2003 to 2007, and after adjustment for inflation, the absolute level of funding from the National Institutes of Health and industry appears to have decreased by 2% in 2008.
European Journal of CancerAlmost all articles on cancer prognostic markers report statistically significant results
226 Citations2007P. Kyzas, Despina Denaxa-Kyza +1 more
Almost all articles on cancer prognostic marker studies highlight some statistically significant results, suggesting that under strong reporting bias, statistical significance loses its discriminating ability for the importance of prognostic markers.
The LancetEffect of a US National Institutes of Health programme of clinical trials on public health and costs
155 Citations2006S. Claiborne Johnston, J. D. Rootenberg +3 more
The public return on investment in clinical trials has been substantial, and although results led to increases in health-care expenditures, health gains were large and valuable.
European Journal of Clinical InvestigationUndue industry influences that distort healthcare research, strategy, expenditure and practice: a review
114 Citations2013Emmanuel Stamatakis, Richard Weiler +1 more
The enormous financial interests involved in the development and marketing of drugs and devices may have given excessive power to these industries to influence medical research, policy, and practice.
The LancetThe James Lind Alliance: tackling research mismatches
89 Citations2010Sophie Petit-Zeman, Lester Firkins +1 more
Health Technology AssessmentA randomised controlled trial of the use of aciclovir and/or prednisolone for the early treatment of Bell's palsy: the BELLS study
79 Citations2009Frank Sullivan, IR Swan +14 more
This study presents robust evidence to support the early use of oral prednisolone in Bell's palsy as cost-effectiveness and shows significant differences by individual treatment (the four-arm model) showed significant differences.
Archives of Internal MedicineStudy of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial
48 Citations2011Samuel D. Krumholz, David Egilman +1 more
The STEPS trial was a seeding trial, used to promote gabapentin and increase prescribing among investigators, and marketing was extensively involved in its planning and implementation.
Journal of Cerebral Blood Flow & MetabolismMethodological Quality of Preclinical Stroke Studies is Not Required for Publication in High-Impact Journals
30 Citations2010Jens Minnerup, Heike Wersching +5 more
The findings show that the quality of animal experimental stroke studies is not relevant for publishing in high-impact journals, and the major predictor for accepting preclinical stroke studies in high -impact journals is the complexity of the investigation into a stroke drug's mode of action.
Journal of the Royal Society of MedicineResearch governance: regulating risk and reducing harm?
22 Citations2005S. E. Shaw